A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs AMG 232 (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Myeloma
- Focus Adverse reactions
- 11 Feb 2019 Status changed from suspended to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 20 Jul 2018 Status changed from recruiting to suspended.